Invitae Corporation (NVTA): Price and Financial Metrics


Invitae Corporation (NVTA): $31.22

-0.07 (-0.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVTA POWR Grades


  • NVTA scores best on the Growth dimension, with a Growth rank ahead of 66.05% of US stocks.
  • NVTA's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • NVTA's current lowest rank is in the Sentiment metric (where it is better than 1.66% of US stocks).

NVTA Stock Summary

  • With a price/sales ratio of 17.15, Invitae Corp has a higher such ratio than 88.76% of stocks in our set.
  • With a year-over-year growth in debt of 68.64%, Invitae Corp's debt growth rate surpasses 88.48% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVTA comes in at -20.35% -- higher than that of only 12.69% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Invitae Corp are RENN, AVCO, XBIT, AGYS, and AMBA.
  • Visit NVTA's SEC page to see the company's official filings. To visit the company's web site, go to www.invitae.com.

NVTA Stock Price Chart Interactive Chart >

Price chart for NVTA

NVTA Price/Volume Stats

Current price $31.22 52-week high $61.59
Prev. close $31.29 52-week low $15.22
Day low $30.56 Volume 2,051,600
Day high $31.64 Avg. volume 4,235,046
50-day MA $32.41 Dividend yield N/A
200-day MA $41.96 Market Cap 6.24B

Invitae Corporation (NVTA) Company Bio


Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.


NVTA Latest News Stream


Event/Time News Detail
Loading, please wait...

NVTA Latest Social Stream


Loading social stream, please wait...

View Full NVTA Social Stream

Latest NVTA News From Around the Web

Below are the latest news stories about Invitae Corp that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Invitae (NVTA) closed at $31.22, marking a -0.22% move from the previous day.

Yahoo | June 11, 2021

Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global technology and medical technology companies.

Yahoo | June 11, 2021

5 Healthcare Stocks to Buy for Their Game-Changing Potential

These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies.

Larry Ramer on InvestorPlace | June 8, 2021

Why Invitae Was Down 17.5% in May

The genetic testing company''s growth isn''t the kind that impresses Wall Street.

The Motley Fool | June 8, 2021

Invitae Corporation (NVTA) CEO Sean George Presents at William Blair 41st Annual Growth Stock Conference (Transcript)

Invitae Corporation (NVTA) William Blair 41st Annual Growth Stock Conference June 03, 2021 4:20 PM ET Company Participants Sean George - CEO, Invitae Corporation Conference Call Participants Brian Weinstein - William Blair Presentation Brian Weinstein Good afternoon. My name is Brian Weinstein and I am the Group Head of Life...

SA Transcripts on Seeking Alpha | June 6, 2021

Read More 'NVTA' Stories Here

NVTA Price Returns

1-mo 12.55%
3-mo -27.29%
6-mo -38.35%
1-year 93.07%
3-year 285.91%
5-year 301.80%
YTD -25.33%
2020 159.21%
2019 45.84%
2018 21.81%
2017 14.36%
2016 -3.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8357 seconds.